Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone

Acute myeloid leukemia developing in patients with autoimmune diseases

“…The first case report of t-AML (M3) in a multiple sclerosis patient was published in 1998. 80 Subsequently, a number of case reports and case series were published on t-AML in mitoxantrone treated patients, [81][82][83][84][85][86][87][88][89][90][91][92][93][94][95][96] as summarized in Table 4. Larger series of patients with multiple sclerosis treated Patients were exposed to a mean cumulative mitoxantrone dose of 60 mg/m 2 and were followed up for a mean of 36 months.…”

Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis

“…10,11 In recent years, an increasing number of APL cases have been reported in MS patients treated with mitoxantrone. 3,5,[12][13][14][15][16][17][18][19][20] However, to date, no attempts have been made to systematically characterize translocation breakpoints in APL cases that developed in this setting.…”

Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis

“…The occurrence of acute promyelocytic leukemia (APL) in MS patients treated with mitoxantrone has been well documented (Table 1). [2][3][4][5][6] We report two new cases of APL in MS patients following treatment with mitoxantrone.…”